Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 11, 2019
[Chronic myeloid leukemia presenting with marked eosinophilia]Yoshihito Haseyama, Yukari Takeda, Koki Kumano
European Journal of Haematology|February 14, 2004
Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphomaKazuki Koizumi, Katsuya Fujimoto, Yoshihito Haseyama, et al.
British Journal of Haematology|March 11, 2014
Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre studyHirozumi Sano, Ryoji Kobayashi, Junji Tanaka, et al.
International Journal of Hematology|June 27, 2019
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity testTakeshi Kondo, Mari Fujioka, Shinichi Fujisawa, et al.
Hematological Oncology|August 17, 2020
Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseasesKatsuya Fujimoto, Kanako C Hatanaka, Yutaka Hatanaka, et al.
Scientific Reports|May 25, 2022
High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemiaHajime Senjo, Masahiro Onozawa, Daisuke Hidaka, et al.
Scientific Reports|November 11, 2020
A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemiaHajime Senjo, Masahiro Onozawa, Daisuke Hidaka, et al.
International Journal of Hematology|March 20, 2026
Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in JapanFumiaki Fujii, Masahiro Onozawa, Shota Yoshida, et al.
International Journal of Hematology|November 5, 2021
Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patientsAkio Mori, Masahiro Onozawa, Daisuke Hidaka, et al.
Haematologica|June 13, 2024
Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study GroupKoh Izumiyama, Tasuku Inao, Hideki Goto, et al.
Pageof 2